Intra-Cellular Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 610
- Market Cap
- $7.8B
- Introduction
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate,...
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 384
- Registration Number
- NCT06372964
- Locations
- 🇺🇸
Clinical Site, Bellevue, Washington, United States
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06299410
- Locations
- 🇺🇸
Clinical Site 1, New Haven, Connecticut, United States
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia or Bipolar Disorder
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06229210
- Locations
- 🇺🇸
Clinical Site, Oklahoma City, Oklahoma, United States
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT05850689
- Locations
- 🇧🇬
Clincal Site, Stara Zagora, Bulgaria
🇪🇸Clinical Site, Zamora, Spain
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT05766813
- Locations
- 🇺🇸
Clinical Site, Milwaukee, Wisconsin, United States
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05732194
- Locations
- 🇺🇸
Clinical Site 1, Miami, Florida, United States
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05470101
- Locations
- 🇺🇸
Clinical Site 1, Saint Louis, Missouri, United States
🇺🇸Clinical Site 2, Creve Coeur, Missouri, United States
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 812
- Registration Number
- NCT05061719
- Locations
- 🇵🇱
Clinical SIte, Toruń, Poland
🇨🇿Clinical site, Brno, Czechia
🇸🇪Clinical Site, Stockholm, Sweden
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT05061706
- Locations
- 🇩🇪
Clinical site, Freiburg im Breisgau, Germany
🇸🇪Clinical Site, Stockholm, Sweden
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 485
- Registration Number
- NCT04985942
- Locations
- 🇨🇿
Clinical site, Plzen, Czechia
🇸🇰Clinical Site, Zlaté Moravce, Slovakia